Abstract
The emergence of Enterobacteriaceae resistant to carbapenem antibiotics (CRE) represents one of the most serious public health challenges in the world. Currently, antibiotic options for the treatment of CRE are very limited, with tigecycline and colistin being the last two treatment options. However, tigecycline resistance and colistin heteroresistance are also rapidly increasing. Klebsie…